Skip to main navigation
  • About
    • Overview
    • Mission & Vision
    • Operating Principles
    • Management
    • Board of Directors
  • Science
    • Overview
    • Therapeutic Areas
    • Therapeutic Platforms
    • Technology Platforms
    • Publications
  • Pipeline
    • Overview
    • Precigen Pipeline
    • Expanded Access Policy
  • Subsidiaries
    • Overview
    • Precigen Actobio
    • Precigen Exemplar
    • Precigen Triple-Gene
  • Careers
    • Overview
    • Job Postings
    • Postdoc Program
    • Benefits
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock
    • Financials
    • Governance
    • Resources
  • Contact
    • Contact
    • Locations
  • About
    • Overview
    • Mission & Vision
    • Operating Principles
    • Management
    • Board of Directors
  • Science
    • Overview
    • Therapeutic Areas
    • Therapeutic Platforms
    • Technology Platforms
    • Publications
  • Pipeline
    • Overview
    • Precigen Pipeline
  • Subsidiaries
    • Overview
    • Precigen Actobio
    • Precigen Exemplar
    • Precigen Triple-Gene
  • Careers
    • Overview
    • Job Postings
    • Postdoc Program
    • Benefits
  • Investors
    • Overview
    • Press Releases
    • Events
    • Stock
    • Financials
    • Governance
    • Resources
  • Contact
    • Contact
    • Locations
PRECIGEN Investors

Press Releases

IR Nav

  • Press Releases
  • Events & Presentations
  • Stock
  • Financials
  • Governance
  • Resources

Press Releases

May 17, 2022
Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference
Learn More
May 09, 2022
Precigen Reports First Quarter 2022 Financial Results and Business Updates
Learn More
Apr 04, 2022
Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Learn More
Mar 01, 2022
Precigen Reports Fourth Quarter and Full Year 2021 Financial Results
Learn More
Jan 12, 2022
Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference
Learn More
Jan 05, 2022
Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference
Learn More

Upcoming Events

May 24, 2022 at 7:00 AM EDT
2022 H.C. Wainwright Global Investment Conference
Helen Sabzevari, President and CEO of Precigen, to participate in a virtual fireside chat.
Read More
Add to Outlook
Add to Google Calendar
Webcast
Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference
Media Kit

Precigen maintains a media kit with our corporate logo and our CEO’s headshot and bio that can be used by media for editorial purposes. Should you have any questions or seek assets not included in our media kit, please contact:

press@precigen.com

Download
Media Kit
Download
Advancing Medicine with precision™
  • About
    • Overview
    • Mission & Vision
    • Operating Principles
    • Management
    • Board of Directors
  • Science
    • Overview
    • Therapeutic Areas
    • Therapeutic Platforms
    • Technology Platforms
    • Publications
  • Pipeline
    • Overview
    • Precigen Pipeline
    • Expanded Access Policy
  • Subsidiaries
    • Overview
    • Precigen Actobio
    • Precigen Exemplar
    • Precigen Triple-Gene
  • Careers
    • Overview
    • Job Postings
    • Postdoc Program
    • Benefits
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock
    • Financials
    • Governance
    • Resources
  • Contact
    • Contact
    • Locations

Headquarters

Precigen, Inc.
20358 Seneca Meadows Parkway
Germantown, MD 20876

Connect

  • linkedin
  • twitter
  • youtube

Privacy and Legal Menu

  • Privacy Policy
  • Legal Notices

Copyright

© Precigen. All Rights Reserved.